Chondrosarcoma in the United States (1973 to 2003): An analysis of 2890 cases from the SEER database

Journal of Bone and Joint Surgery

Volumn 91, Issue 5, 2009, Pages 1063-1072

  Giuffrida, Angela Ylenia ^a   Burgueno, Jorge E ^a   Koniaris, Leonidas G ^a   Gutierrez, Juan C ^a   Duncan, Robert ^b   Scully, Sean P ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHONDROSARCOMA; DATA BASE; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHONDROSARCOMA; DATABASES, FACTUAL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SEER PROGRAM; SEX FACTORS;

EID: 70350061991     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.H.00416     Document Type: Article

References (39)

1. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res. 2007;459:40-47 (Pubitemid 46878192)
2. Curt GA. SEER: report (card) to the nation. Oncologist. 2003;8:507.
3. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2003;8:541-552
4. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12:20-37. (Pubitemid 46143500)
5. Merrill RM, Dearden KA. How representative are the Surveillance, Epidemiology, and End Results (SEER) Program cancer data of the United States? Cancer Causes Control. 2004;15:1027-1034
6. Petrelli NJ. SEER data: it can be thought provoking, but where do we go from here? Ann Surg Oncol. 2007;14:2173-2174
7. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3-18.
8. Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC, Hall HI. Building the infrastructure for nationwide cancer surveillance and control - a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003;14:175-193
9. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) program. 2005. http://seer.cancer.gov/data.
10. Nattinger AB, McAuliffe TL, Schapira MM. Generalizability of the Surveillance, Epidemiology, and End Results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol. 1997;50:939-945
11. Fritz A. Has there been a real drop in the number of expected cancer cases in the United States? Top Health Inf Manage. 1997;17:15-28.
12. Fleming ID. AJCC/TNM cancer staging, present and future. J Surg Oncol. 2001;77:233-236 (Pubitemid 32744190)
13. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 13 Regs Public-Use, Nov 2004 Sub (1973-2002 varying). In: National Cancer Institute D, Surveillance Research Program, Cancer Statistics Branch. http://www.seer.cancer.gov/resources. Accessed 2007 June 1.
14. Katsahian S, Resche-Rigon M, Chevret S, Porcher R. Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution. Stat Med. 2006;25:4267-4278 (Pubitemid 46023771)
15. Latouche A, Porcher R, Chevret S. A note on including time-dependent covariate in regression model for competing risks data. Biom J. 2005;47:807-814 (Pubitemid 43037332)
16. Resche-Rigon M, Azoulay E, Chevret S. Evaluating mortality in intensive care units: contribution of competing risks analyses. Crit Care. 2006;10:R5. (Pubitemid 47079816)
17. The R Project for Statistical Computing. http://www.R-project.org. Accessed 2008 Sep 1.
18. Pintilie M. Analysing and interpreting competing risk data. Stat Med. 2007;26:1360-1367 (Pubitemid 46380846)
19. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706. (Pubitemid 29126745)
20. Rizzo M, Ghert MA, Harrelson JM, Scully SP. Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Relat Res. 2001;391:224-233 (Pubitemid 32954068)
21. Gitelis S, Bertoni F, Picci P, Campanacci M. Chondrosarcoma of bone. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am. 1981;63:1248-1257 (Pubitemid 11022301)
22. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999;81:326-338
23. Marcove RC, Miké V, Hutter RV, Huvos AG, Shoji H, Miller TR, Kosloff R. Chondrosarcoma of the pelvis and upper end of the femur. An analysis of factors influencing survival time in one hundred and thirteen cases. J Bone Joint Surg Am. 1972;54:561-572
24. Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J Bone Joint Surg Am. 2007;89:2113-2123
25. Eriksson AI, Schiller A, Mankin HJ. The management of chondrosarcoma of bone. Clin Orthop Relat Res. 1980;153:44-66.
26. Mankin HJ, Cantley KP, Lippiello L, Schiller AL, Campbell CJ. The biology of human chondrosarcoma. I. Description of the cases, grading, and biochemical analyses. J Bone Joint Surg Am. 1980;62:160-176
27. Björnsson J, McLeod RA, Unni KK, Ilstrup DM, Pritchard DJ. Primary chondrosarcoma of long bones and limb girdles. Cancer. 1998;83:2105-2119 (Pubitemid 28525392)
28. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40(8 Suppl):IV-19-25.
29. McAfee MK, Pairolero PC, Bergstralh EJ, Piehler JM, Unni KK, McLeod RA, Bernatz PE, Payne WS. Chondrosarcoma of the chest wall: factors affecting survival. Ann Thorac Surg. 1985;40:535-541 (Pubitemid 16186095)
30. Ozaki T, Hillmann A, Linder N, Blasius S, Winkelmann W. Metastasis of chondrosarcoma. J Cancer Res Clin Oncol. 1996;122:629-632
31. Pritchard DJ, Lunke RJ, Taylor WF, Dahlin DC, Medley BE. Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer. 1980;45:149-157
32. Sanerkin NG, Gallagher P. A review of the behaviour of chondrosarcoma of bone. J Bone Joint Surg Br. 1979;61:395-400.
33. Scott AD, Crane P, Staunton MD. Chondrosarcoma - local recurrence and systemic embolization. J R Soc Med. 1990;83:48-49 (Pubitemid 20112190)
34. Shaw JH, Castellanos J. Chondrosarcoma. J Maine Med Assoc. 1966;57:157-158
35. Springfield DS, Gebhardt MC, McGuire MH. Chondrosarcoma: a review. Instr Course Lect. 1996;45:417-424
36. Uchida Y, Kawai A, Taguchi K, Yokoi T, Pu J, Inoue H. Clinicopathology of chondrosarcoma. Acta Med Okayama. 1996;50:191-196
37. van Loon CJ, Veth RP, Pruszczynski M, Wobbes T, Lemmens JA, van Horn J. Chondrosarcoma of bone: oncologic and functional results. J Surg Oncol. 1994;57:214-221
38. Wang JW, Ger LP, Shih CH, Hsieh MC. Chondrosarcoma of bone: a statistical analysis of prognostic factors. J Formos Med Assoc. 1991;90:998-1003.
39. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117-1121